$QTRX

Quanterix Corp (QTRX): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Quanterix Corp (QTRX) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 2 exhibit101-qtrxx20260609.htm EX-10.1 Document Exhibit 10.1 Quanterix 900 Middlesex Turnpike | Building 1 Billerica, MA 01821 Jason Faessler Delivered via Email Re: Employment Agreement Dear Jason: Quanterix Corporation (the "Company") is pleased to offer you the full-ti

Original reporting
Published Jun 9, 2026, 12:06 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 12:23 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefCorporate actions
Primary signal
$QTRX
Neutral
medium confidence
Mentioned
$QTRX
Relevance
6/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$QTRXNeutralLow
01

Why it matters

This is a primary disclosure of executive onboarding terms (base salary, bonus target, sign-on equity and cash, vesting, and severance framework). It does not include operational metrics, financial guidance, or material corporate actions.

02

Market read

Company-specific executive appointment with detailed compensation; likely modest sentiment impact absent additional financial or strategic disclosures.

03

What to watch

Traders may focus on the start date (June 22, 2026) and whether the new CFO brings changes to capital allocation, reporting cadence, or investor messaging—none are stated in the filing.

Relevance 6/10Novelty 5/10Timing: Filed pre-market/early session (2026-06-09 08:06 ET) ahead of trading day

Background

The SEC 8-K (Item 5.02) documents the employment agreement and compensatory arrangements for a newly appointed CFO at Quanterix.

Company-level read

Ticker impact

$QTRXNeutralMedium confidence
Context

Quanterix appoints a new CFO (Jason Faessler) with a start date of June 22, 2026 and specified sign-on compensation terms.

Expected impact

Likely limited, short-lived reaction; any move should fade unless paired with operational updates.

Evidence & confidence

An 8-K employment agreement is primary and company-specific, but it does not disclose new financial performance, forecasts, or material transactions beyond compensation/role transition.

Market effects

Minimal; CFO transitions are generally idiosyncratic unless tied to restructuring or guidance changes.

None indicated; role requires presence in Billerica, MA but no broader regional signal.

None indicated; no international operations or cross-border deal disclosed.

Counterpoint

The compensation package (large sign-on cash and equity target) could signal urgency in filling the CFO role, which may precede upcoming financial/strategic updates not yet disclosed.

Key entities

  • Quanterix Corp

    Company filing the 8-K and offering the CFO employment agreement.

  • Jason Faessler

    Appointed Chief Financial Officer with a June 22, 2026 start date and specified compensation/benefits.

  • Everett Cunningham

    CEO reporting line for the new CFO.

Related articles

$QTRXHighAI 9/10

Quanterix (QTRX) Q2 2026 Earnings Call Transcript

Quanterix (QTRX) said Q2 2026 revenue was about $3 million (9%) below May guidance, citing broad-based shortfalls and commercial execution challenges. The company lowered 2026 revenue guidance to $142 million to $148 million from $169 million to $174 million and expects ~$80 million cash by year-end. Quanterix added commercial leaders (Jim Gute, Geoff Albrecht) and reorganized sales, citing Akoya integration savings of $85 million annually.

$QTRXMed

Quanterix Reshapes Sales Strategy, Targets Q4 FDA Decision for Alzheimer’s Blood Test

Quanterix (QTRX) said it completed Akoya Biosciences integration in Q2 and delivered $85M in revenue synergies. It is reshaping sales teams and expects clinical-trial bookings to rise QoQ. For its LucentAD Complete Alzheimer’s blood test, Quanterix filed a 510(k) in January and targets an FDA decision in Q4, possibly into Q1, citing a CMS price crosswalk of $897. It targets $10M diagnostics revenue in 2026.

$QTRXMed

Quanterix Q2 Earnings Call Highlights

Quanterix (NASDAQ:QTRX) reported Q2 cash use of $5.7M and cash of $96.9M. Simoa revenue was $20.6M, Spatial $12.3M, and GAAP gross margin 38.5%. Management guided Q3 revenue flat to slightly above Q2 and cited Akoya integration, $85M annualized savings, and commercial reorganization. FDA timing for LucentAD Complete is targeted for late 2026.

$QTRXHigh

Quanterix Corp (QTRX): Results of Operations and Financial Condition

Quanterix Corp (QTRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2026 Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends

$TTRXMedAI 8/10

Top Biotech Gainers: TTRX Turns Heads, LIXT Shifts To AI Energy, CNXU Update, QTRX, TRAX On Watch

Turn Therapeutics (TTRX) rose over 20% after interim Phase 2 results for GX-03 in atopic dermatitis, with 92.6% achieving EASI-50 at 4 weeks. Conexeu (CNXU) gained ~19% on preclinical B.R.E.A.S.T. bioprinting progress. Rallybio (RLYB) jumped on plans to acquire Avenzo via a $215M investment. LIXTE (LIXT) surged on an AI energy pivot; Quanterix (QTRX) rose on insider SEC filing.